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We present the evolution of testing algorithms at our institution in which the C. Diff Quik Chek Complete immunochromato-
graphic cartridge assay determines the presence of both glutamate dehydrogenase and Clostridium difficile toxins A and B as a
primary screen for C. difficile infection and indeterminate results (glutamate dehydrogenase positive, toxin A and B negative) are
confirmed by the GeneXpert C. difficile PCR assay. This two-step algorithm is a cost-effective method for highly sensitive detec-
tion of toxigenic C. difficile.
The initial observation by Ticehurst and colleagues, which wasconfirmed by others, showing that toxin A/B immunoassays
are insensitive resulted in a reexamination of the manner in which
the laboratory diagnosis of Clostridium difficile infection is done
(6, 8, 24). Two approaches are gaining favor as effective means to
diagnose C. difficile infection (CDI). One is an algorithm in which
detection of C. difficile-specific glutamate dehydrogenase (GDH),
a cell wall antigen, is used as a screening test to be followed by the
demonstration of the presence of toxigenic C. difficile in GDH-
positive stool specimens (6, 8, 16, 18, 19, 20, 26). The presence of
toxigenic C. difficile can be determined by toxin enzyme immuno-
assay (insensitive), cytotoxin neutralization (CTN; relatively sen-
sitive), DNA amplification (most sensitive but perhaps less spe-
cific), or toxigenic culture (most sensitive but quite slow, which
makes it impractical for diagnostic purposes) (1, 2, 17, 26). The
second approach is to directly test stool samples for the presence
of toxigenic C. difficile by using any of four commercially avail-
able, FDA-approved nucleic acid amplification techniques
(NAATs) (3, 5, 9, 10, 11, 12, 13, 14, 22, 23, 26).
In this report, we describe the evolution of testing algorithms
for toxigenic C. difficile in our laboratory. Prior to the implemen-
tation of algorithmic screening for C. difficile testing, our labora-
tory performed a toxin A/B immunoassay daily. The initial C.
difficile screening algorithm used in our laboratory consisted of a
screening test, the C. Diff Quik Chek Complete (TechLab, Blacks-
burg, VA) GDH immunochromatographic cartridge assay (ICA),
that detects GDH only, followed by confirmatory testing with a
CTN assay to confirm the presence of C. difficile toxin in feces (8).
Although a negative result from the initial GDH screening could
be provided quickly by using the GDH ICA, the turnaround time
of the CTN assay is 24 to 48 h. GDH-positive specimens had a 24-h
longer turnaround time than the toxin A/B immunoassay that was
previously performed. Subsequent assay development has shown
that that TechLab C. Diff Quik Chek Complete, which detects
GDH and toxins A and B in a single ICA (GDH-toxin A/B ICA), is
a reliable method to replace the GDH ICA in the initial step of our
algorithm because of the high positive predictive value of the toxin
A/B portion of the assay (18, 19). However, the GDH-toxin A/B
ICA cannot be used as a stand-alone test because of the poor
sensitivity of the toxin A/B portion of the assay (18, 19). We
wanted to determine if a NAAT, the GeneXpert C. difficile (Ceph-
eid, Sunnyvale, CA) PCR assay, could reliably replace our CTN
confirmatory test and thus improve our turnaround time. Several
studies have shown that using a NAAT is a superior diagnostic
approach to using CTN, compared with toxigenic C. difficile cul-
ture (16, 19, 22, 23). Finally we wanted to determine the economic
and clinical impact of this evolved algorithm at our institution.
Consecutive soft or liquid stool specimens from patients at
University of North Carolina Hospitals were submitted for detec-
tion of CDI. Specimens were refrigerated at 4°C and assayed
within 24 h of receipt in the laboratory. This study was approved
by the Biomedical Institutional Review Board of the University of
North Carolina at Chapel Hill.
All specimens were initially screened by GDH-toxin A/B ICA.
Specimens that were negative for GDH were not tested further
because of the reported high negative predictive value of that assay
(10, 20). Confirmatory tests (CTN, GeneXpert PCR) of all GDH-
positive specimens (n  114) were performed. The CTN was per-
formed as previously described (8). The GeneXpert C. difficile
PCR assay was performed according to the manufacturer’s in-
structions. Specimens that were positive or negative by both PCR
and CTN were considered true positive or negative. Discrepant
results were resolved on the basis of the results of toxigenic C.
difficile culture, which was the reference method.
Toxigenic culture of all GDH-positive specimens (n  114)
was performed. Briefly, stool samples were cultured after being
heat shocked at 80°C for 20 min and then inoculated onto cyclo-
serine-cefoxitin fructose agar (CCFA) plates supplemented with
horse blood and chopped meat broth (Remel Laboratories, Le-
nexa, KS), incubated anaerobically, and examined at 48 to 72 h for
colonies consistent with C. difficile. For specimens that were cul-
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ture negative for C. difficile-like organisms on the initial CCFA
plates, a subculture of the chopped meat broth to CCFA was per-
formed and the aforementioned culture process was repeated.
Colonies with morphology consistent with isolates of C. difficile
were then inoculated into chopped meat broth, incubated for 48 h
anaerobically at 35°C, and centrifuged, and then the supernatant
was filtered and assayed to determine the presence of C. difficile
toxin by using CTN as previously described. Clostridium isolates
used for toxin detection were identified by using Vitek ANC cards
(bioMérieux, Durham, NC) according to the manufacturer’s in-
structions. Where necessary, further biochemical analysis to con-
firm identification was also performed. Isolates that were toxi-
genic by CTN and identified by Vitek as C. difficile were
considered toxigenic C. difficile.
We assessed the performance of the GeneXpert C. difficile PCR
as the confirmatory step in the C. difficile testing algorithm as an
alternative to the CTN assay but with a different target. PCR,
CTN, and toxin A/B ICA were performed on 114 GDH-positive
specimens using the GDH-toxin A/B ICA. We found PCR to be
the most sensitive confirmatory method of detecting toxigenic C.
difficile in 70/71 (98.6%) specimens defined as true positives, com-
pared to 47/71 (66.2%) using CTN and only 30/71 (42.3%) using
the toxin A/B portion of the GDH-toxin A/B ICA. (Table 1). On
the basis of these findings, we chose to replace our CTN confir-
matory test with a PCR detecting toxigenic organisms.
We performed a prospective analysis of the two-step algorithm
consisting of GDH-toxin A/B ICA, followed by GeneXpert C. dif-
ficile PCR, with 4,321 specimens over a 12-month period (1 May
2010 to 28 April 2011) (Fig. 1). Results for approximately 87% of
the specimens could be reported after performance of the GDH-
toxin A/B ICA; 13% required PCR confirmation. Quality manage-
ment review of the GDH-toxin A/B ICA-PCR algorithm in our
laboratory for the first quarter of 2011 (data not shown) docu-
mented a median turnaround time of approximately 8 h. All spec-
imens met our stated turnaround time of 24 h. The median 8-h
turnaround time for the GDH-toxin A/B ICA-PCR algorithm was
TABLE 1 Performance of C. Diff Quik Chek Complete ICA, CTN, and










NPVcTP FP TN FN
Toxin ICA 35 4 40 35 42.3 90.9 89.7 53.3
CTN 47 6 37 24 66.2 86 88.6 60.7
PCR 70 8 35 1 98.6 81.4 89.7 97.2
a TP, true positive; FP, false positive; TN, true negative; FN, false negative.
b PPV, positive predictive value.
c NPV, negative predictive value.
FIG 1 Results of two-step algorithm testing for C. Diff Quik Chek Complete ICA and GeneXpert C. difficile PCR.
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due to the performance of testing three times per day, with imme-
diate testing of screen-positive samples with the random-access
GeneXpert system. This is a 1-day turnaround time improve-
ment for GDH-positive specimens over our previously used GDH
ICA-CTN algorithm, which had a stated turnaround time of 48 h
in part because the CTN assay was performed and the result was
reported only once per day. Specimens that were only GDH pos-
itive represented 13.1% of our work load.
Concurrent with the implementation of this new algorithm,
there was an increase in the CDI rate in our institution. Infection
control review (Fig. 2) showed close to a doubling of the CDI rate
in 2010 after the algorithm was introduced compared to that in the
years prior to its implementation (2005 to 2009). We believe that
this increase may have been due, in part, to the increased detection
of C. difficile-positive specimens with the GDH-toxin A/B ICA-
PCR algorithm. We anticipated that there likely would be an in-
crease in the number of CDI cases because of the increased detec-
tion of positive specimens by the GDH ICA-CTN algorithm
observed in the developmental phase of this work.
The GDH-toxin A/B ICA-PCR algorithm not only detects
more positive patients than a GDH ICA-CTN algorithm but is
more economical than a PCR-only testing approach. With the
cost of the GDH-toxin A/B ICA at $11.50 and that of the Gene-
Xpert C. difficile PCR at $37, the cost of goods for the algorithmic
approach described in Fig. 1 was $70,633, while that of a PCR-only
approach would be $159,877.
This study produced four specific findings. (i) We determined,
as have others, that NAAT is a more sensitive method than CTN
for the detection of toxigenic C. difficile in stool samples (Table 1).
Therefore, PCR replaced CTN in our testing algorithm (3, 11, 12,
13, 16, 17, 23). (ii) Institution of the new GDH-toxin A/B ICA-
toxigenic C. difficile PCR algorithm resulted in an improvement of
the turnaround time for the detection of toxigenic C. difficile from
48 h to a maximum of 24 h, with a median turnaround time of 8 h.
(iii) A concordant increase in the number of cases of CDI in our
institution with the change in testing suggests that the new testing
algorithm is detecting an increased number of C. difficile-positive
patients. (iv) Based on the cost of goods, an algorithmic approach
to the diagnosis of CDIs saved our laboratory approximately
$80,000 during the first year of use compared to a PCR-only ap-
proach using the GeneXpert system. Additional savings due to the
capability of discontinuing C. difficile-specific infection control
measures a day earlier because of reduced testing turnaround time
were likely but not evaluated.
The issue of an algorithmic approach using PCR as either the
screening or confirmatory test versus the use of PCR as a stand-
alone test has been a subject of debate (26). A shortcoming of this
study was the inability to obtain clinical information to correlate
with laboratory findings. Thus, replacement of the CTN confir-
matory test with PCR may increase the detection of patients who
are carrying toxigenic organisms but do not have clinical disease.
Carriage of toxigenic organisms for as long as 30 days after the
resolution of symptoms has been described in the literature (21,
25). Some of the patients we studied may, in fact, fit into this
category, but two arguments that this number is relatively small
can be made. First, the increase in the number of CDI cases after
the institution of the GDH-toxin A/B ICA-PCR algorithm was
based on infection prevention chart review and not strictly labo-
ratory findings, although the latter are used as part of the CDI case
definition. Our findings are consistent with those of others who
observed an increase in the number of specimens positive for C.
difficile after the initiation of molecular testing (7, 14). Second, we
have strictly enforced rules in place in our laboratory that allow
only the testing of diarrheic stool samples and no testing of cure
stool specimens without consultation with a laboratory director
(4). These clinical rules should reduce the number of PCR-posi-
tive patients who are potential toxigenic C. difficile carriers.
The estimated cost savings of using an algorithmic testing ap-
proach versus a PCR-only approach we report may be excessive. It
can be argued that the greater sensitivity of PCR could lead to
reduced testing of repeat specimens. In one study, it was estimated
that 20% of tests could be eliminated (15). If we went to an all-
PCR testing approach in our laboratory, even with the 20% sav-
ings, the cost of the goods used in this approach would be $58,000
more per year than with the algorithmic approach. The test that
we used in our study has the highest cost of the four FDA-ap-
proved C. difficile NAATs. Since the reported performance char-
acteristics of the four NAATs are similar (3, 4, 10, 11, 12, 13, 16, 17,
22, 23), it is likely that the other three NAATs could be used in an
algorithmic approach with similar results. This would have two
impacts, i.e., reduction of the cost of the algorithmic approach and
narrowing of the cost difference between the algorithmic and
NAAT-only approaches. Two reasons why we used the GeneXpert
C. difficile PCR are (i) its ease of use, which allows it to be per-
formed on all shifts by personnel who do not have extensive train-
ing in molecular techniques, and (ii) the fact that the GeneXpert
system is random access and does not require batching as other
systems do, thus keeping the turnaround time to a minimum.
What would be the advantages and disadvantages of an all-
NAAT approach? Fang et al. (26) and others (10, 16, 23) have
argued that more true-positive patients would be found because
of the method’s enhanced sensitivity. What is less certain is what
percentage of C. difficile NAAT-positive patients are GDH nega-
tive and thus would be missed by the algorithm presented in this
study. A large study by Peterson and colleagues that carefully ex-
amined this issue showed that PCR would detect approximately
1% more positives than the GDH test but that the difference from
detection by toxigenic C. difficile culture is not statistically signif-
icant (17). As a result, we allow physicians, by request, to bypass
the first step in the algorithm and go directly to PCR. Thus far,
with a small number of specimens (10), we have found no PCR
positives, but on the basis of the Peterson data, we would need to
test approximately 100 specimens to find one additional positive.
In a setting where NAAT is readily available as a confirmatory
FIG 2 CDI rates prior to and after the institution of a two-step algorithm with
PCR for toxigenic C. difficile as the confirmatory method.
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test, a GDH-toxin A/B combination ICA is likely to be of very little
value, as has been argued by others (9). The value of this test lies in
its speed in settings where confirmatory tests have to be sent to
reference laboratories, as is the case at one of our small satellite
hospitals that performs the GDH-toxin A/B ICA test and refers
GDH-positive/toxin-negative specimens to our institution. Data
presented here and elsewhere suggest that the toxin A/B portion of
the GDH-toxin A/B ICA has a positive predictive value of 90 to
100%, allowing positives to be reported without further testing
(18, 19). Results from our prospective study (Fig. 1) indicate that
when the GDH-toxin A/B ICA is used, 36% of the positive results
(191/533) and 94% of the negative results (3564/3788) could be
reported within 30 min. Confirmation of GDH-positive/toxin-
negative results would be dependent on the confirmatory test
turnaround time at the reference laboratory. If a laboratory chose
to perform GDH ICA-PCR instead of GDH-toxin A/B-PCR, on
the basis of our data, it would cost an additional $7,067/year.
The GDH-toxin A/B ICA-PCR algorithm not only detects
more toxigenic C. difficile-positive patients than our initial GDH
ICA-CTN algorithm but also detects them more quickly. The new
algorithm influenced the detection of a larger nosocomial CDI
problem in our institution than previously appreciated. With the
advent of mandatory reporting of nosocomial infection rates, im-
proved diagnostics for C. difficile become a double-edged sword,
on the one hand improving diagnostic accuracy while on the other
hand increasing detection and thus nosocomial infection rates.
The hope, then, is that improved C. difficile diagnostics will lead to
improved infection prevention interventions and eventually de-
clining rates of infections due to this important nosocomial
pathogen.
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